Evaluation of low dose continuous infusion 5‐fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer

• Publication date

  1994-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19940801)74:3<916::AID-CNCR2820740319>3.0.CO;2-ZPMID 8039119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytotoxic chemotherapy for advanced renal cell carcinoma.

  1993cited by this paper
• Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.

  1990cited by this paper
• Low‐dose continuous infusion 5‐fluorouracil. Evaluation in advanced breast carcinoma

  1989cited by this paper
• Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.

  1988cited by this paper
• Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.

  1985cited by this paper
• DNA determinations for prognosis and therapy control in prostatic cancer.

  1983cited by this paper
• Cancer chemotherapy via ambulatory infusion pump

  1983cited by this paper
• Protracted ambulatory venous infusion of 5-fluorouracil.

  1983cited by this paper

• Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

  2020cites this paper
• Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.

  2015cites this paper
• Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.

  2013cites this paper
• Phase I Trial of Sorafenib in Combination With 5‐Fluorouracil/Leucovorin in Advanced Solid Tumors

  2012cites this paper
• Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

  2012cites this paper
• Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma

  2011cites this paper
• A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

  2010cites this paper
• A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma

  2010cites this paper
• A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma

  2008cites this paper
• A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

  2008cites this paper
• The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

  2008cites this paper
• Cytotoxic Chemotherapy for Metastatic Renal Cell Cancer

  2008cites this paper
• Chemotherapy for Metastatic Clear-Cell Renal Cell Carcinoma

  2008cites this paper
• [Current strategies in the treatment of renal-cell cancer: targeted therapies].

  2008cites this paper
• Estrategias actuales en el tratamiento del carcinoma de células renales: fármacos dirigidos a dianas moleculares

  2008cites this paper
• Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC

  2007cites this paper
• Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC)

  2007cites this paper
• Modulation of p21‐activated kinase 1 alters the behavior of renal cell carcinoma

  2007cites this paper
• Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches

  2006influential citation
• A phase II study of gemcitabine and capecitabine in metastatic renal cancer

  2006cites this paper
• Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma

  2005cites this paper
• Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

  2005cites this paper
• A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma

  2005cites this paper
• Gene expression profiling of renal cell carcinoma and clinical implications.

  2005cites this paper
• Targeted agents for the treatment of advanced renal cell carcinoma

  2005cites this paper
• The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients

  2004cites this paper
• Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

  2004cites this paper
• Long-term treatment of metastatic renal-cell carcinoma with fluorouracil.

  2004cites this paper
• Treatment of recurrent or metastatic renal cell carcinoma

  2004cites this paper
• Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

  2004cites this paper
• The role of systemic chemotherapy in the treatment of kidney cancer.

  2003cites this paper
• A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

  2002cites this paper
• Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.

  2001cites this paper
• The clinical pharmacology of the oral fluoropyrimidines.

  2001cites this paper
• Granulocyte‐macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma

  2000cites this paper
• Systemic therapy for renal cell carcinoma.

  2000cites this paper
• Chemotherapy for renal cell carcinoma.

  2000cites this paper
• Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.

  2000cites this paper
• Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

  2000cites this paper
• Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma.

  1999cites this paper
• Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial

  1999cites this paper
• Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer.

  1999cites this paper
• Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.

  1998cites this paper
• Antitumor Effect of Irinotecan Hydrochloride (CPT‐11) on Human Renal Tumors Heterotransplanted in Nude Mice

  1998cites this paper
• Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.

  1997cites this paper
• A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

  1996cites this paper